IBIO
iBio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 0
Bearish signal 2
Low Cash Short-term Debt Ratio
Three Black Crows
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IBIO
Ibio, Inc.
A biotechnology company that utilizes artificial intelligence and advanced computational biology to develop next-generation biopharmaceutical products
11750 Sorrento Valley Road, Suite 200, San Diego, CA 92121
--
IBio, Inc., incorporated under the laws of Delaware on April 17, 2008 as iBioPharma, Inc., merged with Biotechnologies, Inc., New Jersey on July 25, 2008 and changed its name to iBio, Inc. on August 10, 2009. IBio is a preclinical stage biotechnology company that uses the power of artificial intelligence (AI) to develop precision antibodies. The company's proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope guidance and monoclonal antibody (mAb) optimization.
Company Financials
EPS
IBIO has released its 2026 Q1 earnings. EPS was reported at -0.11, versus the expected -0.07, missing expectations. The chart below visualizes how IBIO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IBIO has released its 2026 Q1 earnings report, with revenue of 100.00K, reflecting a YoY change of NaN%, and net profit of -5.72M, showing a YoY change of -43.39%. The Sankey diagram below clearly presents IBIO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
